Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,102.44
-712.12(-1.83%)
Hang Seng
17,936.12
-5.66(-0.03%)
FTSE 100
8,145.67
-1.19(-0.01%)
Bitcoin USD
65,546.46
-972.52(-1.46%)
CMC Crypto 200
1,368.69
-19.47(-1.40%)

Clinuvel Pharmaceuticals Limited (CUV.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD

Add to watchlist

14.64

-0.14

(-0.96%)

At close: 03:59PM AEST

Loading interactive chart…

Simply Wall St.
Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company
Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...
Simply Wall St.
Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswire
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years